News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

|Videos|November 24, 2020

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

Author(s)Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC, Robert Naismith, MD, Bianca Weinstock-Guttman, MD

Episodes in this series

EP. 1 Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

EP. 1 Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

EP. 2 OLKIOS: Looking at Ofatumumab’s Continued Efficacy

EP. 2 OLKIOS: Looking at Ofatumumab’s Continued Efficacy

EP. 3 OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

EP. 3 OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

EP. 4 Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

EP. 4 Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

EP. 5 Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

EP. 5 Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

EP. 6 Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

EP. 6 Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

EP. 7 OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

EP. 7 OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

EP. 8 OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

EP. 8 OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

EP. 9 Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

EP. 9 Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

EP. 10 Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

EP. 10 Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

EP. 11 Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

EP. 11 Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

EP. 12 Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

EP. 12 Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

EP. 13 CLARITY Extension Trial: Disability Improvement With Cladribine

EP. 13 CLARITY Extension Trial: Disability Improvement With Cladribine

EP. 14 COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

EP. 14 COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

EP. 15 Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

EP. 15 Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

Phase 4 Study Highlights Valbenazine's Positive Impact on Patient-Reported Quality of Life, Daily Functioning in Tardive Dyskinesia

ByIsabella Ciccone, MPH

September 6th 2026

uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players

ByNeurologyLive® Staff

September 5th 2026

NeurologyLive® Friday 5 — September 4, 2026

ByIsabella Ciccone, MPH

September 4th 2026

Study Identifies Greater Symptom Burden at Parkinson Diagnosis in Patients With Amyloid Copathology

ByIsabella Ciccone, MPH

September 4th 2026

National Analysis Reveals Certified Headache Specialists Absent From More Than 90% of US Counties

ByIsabella Ciccone, MPH

September 4th 2026

Latest CME

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players

American Academy of Neurology, American Headache Society Issue Updated Guideline on Migraine Prevention

uniQure Submits BLA for Gene Therapy in Huntington Disease

FDA Approves Zilganersen, First Treatment for Alexander Disease

Study Shows DMTs Associated With Higher Risk of Gynecologic Complications in Women With MS